Therapeutic Asset Ratings
373 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Daraxonrasib
Pancreatic Cancer
Revolution Medicines, Inc.
P3
CCC
(54)
ibi343
Pancreatic Cancer
Zhejiang University
P3
CCC
(54)
Ruxolitinib
Pancreatic Cancer
Incyte Corporation
P3
CCC
(54)
Adebrelimab
Pancreatic Cancer
Jinling Hospital, China
P2
CCC
(54)
Atezolizumab
Pancreatic Cancer
Cancer Research UK
P2
CCC
(54)
Avutometinib
Pancreatic Cancer
Washington University School of Medicine
P2
CCC
(54)
Defactinib
Pancreatic Cancer
Washington University School of Medicine
P2
CCC
(54)
Famitinib
Pancreatic Cancer
Fudan University
P2
CCC
(54)
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Pancreatic Cancer
National University of Malaysia
P2
CCC
(53)
Bms-907351
Pancreatic Cancer
Joseph Kim
P2
CCC
(53)
Catequentinib
Pancreatic Cancer
RenJi Hospital
P2
CCC
(53)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Pancreatic Cancer
Sensei Biotherapeutics, Inc.
P2
CCC
(53)
LIDOCAINE
Pancreatic Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
P2
CCC
(53)
Niraparib
Pancreatic Cancer
Tempus AI
P2
CCC
(53)
Olaparib
Pancreatic Cancer
Cambridge University Hospitals NHS Foundation Trust
P2
CCC
(53)
Ponsegromab
Pancreatic Cancer
Pfizer
P2
CCC
(53)
Surufatinib
Pancreatic Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
P2
CCC
(53)
Solu-Cortef
Pancreatic Cancer
Helsinki University Central Hospital
P4
CCC
(52)
PROPOFOL
Pancreatic Cancer
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
P3
CCC
(52)
Losartan
Pancreatic Cancer
Tanta University
P2
CCC
(52)
Tas-102
Pancreatic Cancer
National Cancer Institute (NCI)
P2
CCC
(52)
Cediranib
Pancreatic Cancer
City of Hope Medical Center
P1
CCC
(52)
Gx
Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
P2/3
CCC
(52)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Pancreatic Cancer
Cancer Research UK
P2/3
CCC
(52)
Budigalimab
Pancreatic Cancer
Trishula Therapeutics, Inc.
P2
CCC
(51)
Showing 51 to 75 of 373 assets
Previous
Page 3 of 15
Next